Clinical guideline for pharmacological management of cancer pain: The Japanese society of palliative medicine recommendations

Japanese Journal of Clinical Oncology

Volumn 43, Issue 9, 2013, Pages 896-909

  Yamaguchi, Takashi ^a,b   Shima, Yasuo ^c   Morita, Tatsuya ^d   Hosoya, Miki ^e   Matoba, Motohiro ^e  

^a TEINE KEIJINKAI HOSPITAL   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c TSUKUBA MEDICAL CENTER HOSPITAL   (Japan)

^d SEIREI MIKATAHARA GENERAL HOSPITAL   (Japan)

^e NATIONAL CANCER CENTER   (Japan)

Author keywords

Cancer pain; Guideline; Nonopioid analgesics; Opioid analgesics

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; CORTICOSTEROID; LIDOCAINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL;

ARTICLE; BONE METASTASIS; BONE PAIN; BREAKTHROUGH PAIN; CANCER PAIN; CANCER PALLIATIVE THERAPY; CONSTIPATION; DELIRIUM; DROWSINESS; EPIGASTRIC PAIN; HUMAN; NAUSEA AND VOMITING; NERVE BLOCK; NEUROPATHIC PAIN; PAIN ASSESSMENT; PANCREAS CANCER; PATIENT EDUCATION; PRACTICE GUIDELINE;

CANCER PAIN; GUIDELINE; NONOPIOID ANALGESICS; OPIOID ANALGESICS;

ANALGESICS; ANALGESICS, OPIOID; ANTI-ARRHYTHMIA AGENTS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; HUMANS; JAPAN; NEOPLASMS; NEURALGIA; PAIN; PAIN MANAGEMENT; PAIN MEASUREMENT; PALLIATIVE CARE; RECEPTORS, N-METHYL-D-ASPARTATE; SEVERITY OF ILLNESS INDEX;

EID: 84883320374     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyt099     Document Type: Article

References (86)

1. Takashi Yamaguchi, Minoru Narita, Tatsuya Morita, Yoshiyuki Kizawa, Motohiro Matoba. Recent developments in the management of cancer pain in Japan: education, clinical guidelines, and basic researches. Jpn J Clin Oncol 2012;42:1120-7.
2. Teunissen SCCM, Wesker W, Kruitwagen C, de Haes HCJM, Voest EE, de GraeffA. Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage 2007;34:94-104.
3. van den Beuken-van Everdingen M, de Rijke J, Kessels A, Schouten H, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 2007;18:1437-49.
4. Deandrea S, Montanari M, Moja L, et al. Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol 2008; 19:1985-91.
5. Yamagishi A, Morita T, Miyashita M, et al. Pain intensity, quality of life, quality of palliative care, and satisfaction in outpatients with metastatic or recurrent cancer: a Japanese, nationwide, region-based, multicenter survey. J Pain Symptom Manage 2012;43:503-14.
6. Morita T, Fujimoto K, Namba M, et al. Palliative care needs of cancer outpatients receiving chemotherapy: an audit of a clinical screening project. Support Care Cancer 2007;16:101-7.
7. Yamagishi A, Morita T, Miyashita M, Kimura F. Symptom prevalence and longitudinal follow-up in cancer outpatients receiving chemotherapy. J Pain Symptom Manage 2009;37:823-30.
8. Cherny N, Ripamonti C, Pereira J, et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 2001;19:2542-54.
9. Hanks GW, Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001;84: 587-93.
10. Jost L. Management of cancer pain: ESMO clinical recommendations. Ann Oncol 2007;18:ii92-4.
11. Kvale PA, Selecky PA, Prakash UBS. Palliative care in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132:368S-403S.
12. Mercadante S, Radbruch L, Caraceni A, et al. Episodic (breakthrough) pain. Cancer 2002;94:832-9.
13. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology, Adult Cancer Pain. http://www.nccn.org/professionals/physician_gls/PDF/pain.pdf
14. Japanese Society for Palliative Medicine. The evidence-based medicine-supported cancer pain management guideline. Shinko Trading Co Ltd. 2000. (in Japanese).
15. Guyatt GH, Oxman AD, Visit GE, et al. GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6.
16. Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012;13:e58-68.
17. Leser JD, Butler SH, Chapman CR, Turk DC, editors. Bonica's Management of Pain, 3rd ed. LippincottWilliams &Wilkins, 2001. 18. Berger AM, Shuster JL, Von Roenn JH, editors. Principles and Practice of Palliative Care and Supportive Oncology, 3rd ed. Lippincott Williams &Wilkins, aWolters Kluwer Business, 2007.
18. Berger AM, Shuster JL, Von Roenn JH, editors. Principles and Practice of Palliative Care and Supportive Oncology, 3rd ed. Lippincott Williams &Wilkins, aWolters Kluwer Business, 2007.
19. Doyle D, Hanks GWC, Cherny NI, Calman K, editors. Oxford Textbook of Palliative Medicine, 3rd ed. Oxford University Press, 2005.
20. McMahon SB, Koltzenburg M, editors. Wall and Melzack's Textbook of Pain, 5th ed. Elsevier Churchill Livingstone, 2006.
21. Walsh D, editors. Palliative Medicine. Saunders Elsevier, 2009. 22. Bruera E, Higginson IJ, Ripamonti C, von Gunten C, editors. Textbook of Palliative Medicine. London: Hodder Arnold, 2006.
22. Bruera E, Higginson IJ, Ripamonti C, von Gunten C, editors. Textbook of Palliative Medicine. London: Hodder Arnold, 2006.
23. Fitch K, Bernstein SJ, Aguilar MD, et al. The Rand/UCLA Appropriateness Method User's manual. Santa Monica, CA: RAND, 2001.
24. Stambaugh JE, Jr. Additive analgesia of oral butorphanol/acetaminophen in patients with pain due to metastatic carcinoma. Curr Ther Res 1982;31:386-92.
25. McNicol E, Strassels SA, Goudas L, et al. NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database Syst Rev 2005;Jan 25;(1):CD005180.
26. Moertel CG, Ahmann DL, Tylor WF, et al. Aspirin and pancreatic cancer pain. Gastroenterology 1971;60:552-3.
27. Moertel CG, Ahmann DL, Tylor WF, et al. Relief of pain by oral medications. A controlled evaluation of analgesic combinations. JAMA 1974;229:55-9.
28. Stambaugh JE, Jr, Drew J. A double-blind parallel evaluation of the efficacy and safety of single dose of ketoprofen in cancer pain. J Clin Pharmacol 1988;28:S34-9.
29. Saxena A, Andley M, Gnanasekaran N. comparison of piroxicam and acetylsalicylic acid for pain in head and neck cancers: a double-blind study. Palliat Med 1994;8:223-9.
30. Turnbull R, Hills LJ. Naproxen versus aspirin as analgesics in advanced malignant disease. J Palliat Care 1986;1:25-8.
31. Ventafridda V, Toscani F, Tamburini M, et al. Sodium naproxen versus sodium diclofenac in cancer pain control. Arzneimittelforschung 1990; 40:1132-4.
32. Ventafridda V, de Conno F, Panerai AE, et al. Non-steroidal antiinflammatory drugs as the first step in cancer pain therapy: double-blind, within-patient study comparing nine drugs. J IntMed Res 1990;18:21-9.
33. Evidence-based Gastric Ulcer Treatment Guideline Committee. Evidence-based Gastric Ulcer Treatment Guideline. 2nd ed. Jihou, 2007. (in Japanese).
34. Ventafridda V, Tamburini M, Caraceni A, et al. Validation study of the WHO method for cancer pain relief. Cancer 1987;59:850-6.
35. Azevedo Sao Leao Ferreira K, Kimura M, Jacobsen Teixeira M. The WHO analgesic ladder for cancer pain control, twenty years of use. How much pain relief does one get from using it? Support Care Cancer 2006;14:1086-93.
36. Marinangeli F, Ciccozzi A, Leonardis M, et al. Use of strong opioids in advanced cancer pain: a randomized trial. J Pain Symptom Manage 2004;27:409-16.
37. Maltoni M, Scarpi E, Modonesi C, et al. A validation study of the WHO analgesic ladder: a two-step vs three-step strategy. Support Care Cancer 2005;13:888-94.
38. Wiffen PJ, McQuay HJ. Oral morphine for cancer pain. Cochrane Database Syst Rev 2007;Oct 17;(4):CD003868.
39. Silvestri B, Bandieri E, Del Prete S, et al. Oxycodone controlled-release as first-choice therapy for moderate-to-severe cancer pain in Italian patients: results of an open-label, multicentre, observational study. Clin Drug Investig 2008;28:399-407.
40. Reid CM, Martin RM, Sterne JA, et al. Oxycodone for cancer-related pain: meta-analysis of randomized controlled trials. Arch Intern Med 2006;166:837-43.
41. Lauretti GR, Oliveira GM, Pereira NL. Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients. Br J Cancer 2003;89:2027-30.
42. Wong JO, Chiu GL, Tsao CJ, Chang CL. Comparison of oral controlled-release morphine with transdermal fentanyl in terminal cancer pain. Acta Anesthesiol Sin 1997;35:25-32.
43. Kress HG, Von der Laage D, Hoerauf KH, et al. A randomized, open, parallel group, multicenter trial to investigate analgesic efficacy and safety of a new transdermal fentanyl patch compared to standard opioid treatment in cancer pain. J Pain Symptom Manage 2008;36:268-79.
44. Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manage 1997;13:254-61.
45. Hunt R, Fazekas B, Thorne D, Brooksbank M. A comparison of subcutaneous morphine and fentanyl in hospice cancer patients. J Pain Symptom Manage 1999;18:111-9.
46. Mystakidou K, Tsilika E, Parpa E, et al. Long-term cancer pain management in morphine pre-treated and opioid naive patients with transdermal fentanyl. Int J Cancer 2003;107:486-92.
47. Vielvoye-Kerkmeer AP, Mattern C, Uitendaal MP. Transdermal fentanyl in opioid-naive cancer pain patients: an open trial using transdermal fentanyl for the treatment of chronic cancer pain in opioid-naive patients and a group using codeine. J Pain Symptom Manage 2000;19:185-92.
48. van Seventer R, Smit JM, Schipper RM, et al. Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain. Curr Med Res Opin 2003;19:457-69.
49. Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage 2004;28:497-504.
50. Ben-Ahron I, Gafter-Gvil A, Paul M, et al. Interventions for alleviating cancer-related dyspnea: a systematic review. J Clin Oncol 2008;26:2396-404.
51. Stambaugh JE, Reder RF, Stambaugh MD, et al. Double-blinded, randomized comparison of the analgesic and pharmacokinetic profiles of controlled- and immediate-release oral oxycodone in cancer pain patients. J Clin Pharmacol 2001;41:500-6.
52. Stambaugh JE, Jr, Drew J. The combination of ibuprofen and oxycodone/acetaminophen in the management of chronic cancer pain. Clin Pharmacol Ther 1988;44:665-9.
53. Bjorkman R, Ullman A, Hedner J. Morphine-sparing effect of diclofenac in cancer pain. Eur J Clin Pharmacol 1993;44:1-5.
54. Mercadante S, Fulfaro F, Casuccio A. A randomised controlled study on the use of anti-inflammatory drugs in patients with cancer pain on morphine therapy: effects on dose-escalation and a pharmacoeconomic analysis. Eur J Cancer 2002;38:1358-63.
55. Stockler M, Vardy J, Pillai A, et al. Acetaminophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: a randomized, double-blind, placebo-controlled cross-over trial. J Clin Oncol 2004;22:3389-94.
56. Quigley C. Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev. 2004;CD004847.
57. Mercadante S, Bruera E. Opioid switching: a systematic and critical review. Cancer Treat Rev 2006;32:304-15.
58. Mercadante S, Villari P, Ferrera P, et al. Addition of another opioid may improve opioid response in cancer pain: preliminary data. Support Care Cancer 2004;12:762-6.
59. Drexel H, Dzien A, Spiegel RW, et al. Treatment of severe cancer pain by low-dose continuous subcutaneous morphine. Pain 1989;36:169-76.
60. Enting RH, Oldenmenger WH, van der Rijt CC, et al. A prospective study evaluating the response of patients with unrelieved cancer pain to parenteral opioids. Cancer 2002;94:3049-56.
61. Bell R, Eccleston C, Kalso E. Ketamine as an adjuvant to opioids for cancer pain. J Pain Symptom Manage 2003;26:867-75.
62. Bruera E, Roca E, Cedaro L, et al. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 1985;69:751-4.
63. Mercadante SL, Berchovich M, Casuccio A, et al. A prospective randomized study of corticosteroids as adjuvant drugs to opioids in advanced cancer patients. Am J Hosp Palliat Care 2007;24:13-9.
64. Zeppetella G, Ribeiro MD. Opioids for the management of breakthrough (episodic) pain in cancer patients. Cochrane Database Syst Rev 2006;CD004311.
65. Coluzzi PH, Schwartzberg L, Conroy JD, Jr, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC (R)) and morphine sulfate immediate release (MSIR (R)). Pain 2001;91:123-30.
66. Mercadante S, Villari P, Ferrera P, et al. Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose. J Pain Symptom Manage 2004;27:352-9.
67. Mercadante S, Intravaia G, Villari P, et al. Intravenous morphine for breakthrough (episodic-) pain in an acute palliative care unit: a confirmatory study. J Pain Symptom Manage 2008;35:307-13.
68. Mercadante S, Villari P, Ferrera P, et al. Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic breakthrough pain. Br J Cancer 2007;96:1828-33.
69. Enting RH, Mucchiano C, Okdenmenger WH, et al. The 'pain pen' for breakthrough cancer pain: a promising treatment. J Pain Symptom Manage 2005;29:213-7.
70. Tod J, Rees E, Gwilliam B, et al. An assessment of the efficacy and tolerability of a 'double dose'of normal-release morphine sulphate at bedtime. Palliat Med 2002;16:507-12.
71. Dale O, Piribauer M, Kaasa S, et al. A double-blind, randomized, crossover comparison between single-dose and double-dose immediate-release oral morphine at bedtime in cancer patients. J Pain Symptom Manage 2009;37:68-76.
72. Caraceni A, Zecca E, Bonezzi C, et al. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the gabapentin cancer pain study group. J Clin Oncol 2004;22:2909-17.
73. Keskinbora K, Pekel AF, Aydinli I, et al. Gabapentin and an opioid combination versus opioid alone for the management of neuropathic cancer pain: a randomized open trial. J Pain Symptom Manage 2007;34:183-9.
74. Wiffen PJ, McQuay HJ, Moore RA, et al. Gabapentin for acute and chronic pain. Cochrane Database Syst Rev 2005;Jul 20;(3):CD005452. 75. Yajnik S, Singh GP, Singh G, Kumar M. Phenytoin as a coanalgesic in cancer pain. J Pain Symptom Manage 1992;7:209-13.
75. Yajnik S, Singh GP, Singh G, Kumar M. Phenytoin as a coanalgesic in cancer pain. J Pain Symptom Manage 1992;7:209-13.
76. Hardy JR, Rees EAJ, Gwilliam B, Ling J. A phase ? study to establish the efficacy and toxicity of sodium valproate in patients with cancer-related neuropathic pain. J Pain Symptom Manage 2001;21:204-9.
77. Hugel H, Ellershaw JE, Dickman A. Clonazepam as an adjuvant analgesic in patients with cancer-related neuropathic pain. J Pain Symptom Manage 2003;26:1073-4.
78. Mercadante S, Arcuri E, Tirelli W. Amitriptyline in neuropathic cancer pain in patients on morphine therapy: a randomized placebo-controlled, double-blind crossover study. Tumori 2002;88:239-42.
79. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2007;Oct 17;(4):CD005454.
80. Sharma S, Rajagopal MR, Palat G, et al. A phase ? pilot study to evaluate use of intravenous lidocaine for opioid-refractory pain in cancer patients. J Pain Symptom Manage 2009;37:85-93.
81. Ellemann K, Sjogren P, Banning AM, et al. Trial of intravenous lidocaine on painful neuropathy in cancer patients. Clin J Pain 1989;5: 291-4.
82. Bruera E, Ripamonti C, Brenneis C, et al. A randomized double-blind crossover trial of intravenous lidocaine in the treatment of neuropathic cancer pain. J Pain Symptom Manage 1992;7:138-40.
83. Challapalli V, Tremont-Lukats IW, McNicol ED, et al. Systemic administration of local anesthetic agents to relieve pain. Cochrane Database Syst Rev 2005;Oct 19;(14):CD003345.
84. Mercadante S, Arcuri E, Tirelli W, et al. Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. J Pain Symptom Manage 2000;20:246-51.
85. Jackson K, Ashby M, Martin P, et al. 'Burst' ketamine for refractory cancer pain: an open-label audit of 39 patients. J Pain Symptom Manage 2001;22:834-42.
86. Kannan TR, Saxena A, Bhatnagar S, et al. Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients. J Pain Symptom Manage 2002;23:60-5.